Phase 2 - Rhythmic Light Therapy for Alzheimer's Disease Patients
NCT: NCT05016219 · RECRUITING
Brief Summary
Participants will randomly be placed into one of four groups and experience one of the four following conditions: (1) a placebo light that provides a 40 hertz (Hz) flicker (rhythmic light \[RL\]); (2) a placebo light with a random flicker (placebo condition for rhythmic light); (3) a light source that will stimulate the circadian system and provides a 40 Hz flicker (RL); or (4) a light source that will stimulate the circadian system and provides a random flicker (placebo condition for rhythmic light). Following a baseline week, participants will experience his/her assigned lighting condition for two hours in the morning for 8 weeks. After a 4-week washout period, a final round of assessments will be obtained. Study assessments (except for the Pittsburgh Sleep Quality Index and Montreal Cognitive Assessment) will be collected at the end of each week, for a total of 8 assessments.
Frequently Asked Questions
What is Phase 2 - Rhythmic Light Therapy for Alzheimer's Disease Patients?
Phase 2 - Rhythmic Light Therapy for Alzheimer's Disease Patients is a clinical trial registered under NCT05016219. Current status: RECRUITING.
What is the status of NCT05016219?
The current status of NCT05016219 (Phase 2 - Rhythmic Light Therapy for Alzheimer's Disease Patients) is: RECRUITING.
When did Phase 2 - Rhythmic Light Therapy for Alzheimer's Disease Patients start?
Phase 2 - Rhythmic Light Therapy for Alzheimer's Disease Patients started on 2023-08-22.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.